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Abstract Co-amplification of the centromere on chromo-
some 17 (CEP17) and HER2 can occur in breast cancer.
Such aberrant patterns (clusters) on CEP17 can be mis-
leading to calculate the HER2/CEP17 ratio, and thus
underreporting of HER2 amplification. We identified 14
breast cancers retrospectively with HER2/CEP17
co-amplification and performed FISH (fluorescence in situ
hybridization) with additional chromosome 17 probes
(17p11.1–q11.1, 17p11.2–p12, TP53 on 17p13.1, RARA on
17q21.1–3 and TOP2 on 17q21.3–22) to characterize the
spanning of the amplicon in these cases. Furthermore, the
HER2 status was analyzed by means of HER2 silver in situ
hybridization (SISH) and immunohistochemistry (IHC).
The co-amplification of HER2/CEP17 was compared
between the three institutions. TP53 was eusomic in all
cases, 17p11.2–p12 in 79% (11/14), whereas 17p11.1–q11.1
showed chromosomal gain in all cases. RARA was amplified
in 10/14 cases (71%) and TOP2 in 3/14 cases (21%). HER2
was amplified with FISH/SISH in all 14 cases. 9/14 tumors
were 3? IHC positive (64%) and 3 cases were 2? IHC
positive. In our cohort the CEP17 amplicon almost always
involves the HER2 but not the TOP2 locus. Overall agree-
ment on HER2/CEP17 ratio (when applying ASCO/CAP
guidelines) was only 64% (9/14 cases) between the institu-
tions. Discrepant ratios varied from 1.1 to 14.3. The HER2/
CEP17 co-amplification is not defined in the ASCO/CAP
guidelines, and may result in inaccurate HER2-FISH/SISH
status, particularly if only the calculated HER2/CEP17 ratio
is reported. It is recommended to report separate CEP17 and
HER2 signals in complex HER2/CEP17 patterns.
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Introduction
Therapeutic response to Herceptin
TM
in HER2 positive
breast cancer can be predicted by the HER2 status in
routine diagnostic testing, which has been established by
IHC and in situ hybridization (FISH/SISH/CISH) technol-
ogy [30]. Depending on the applied test, the current diag-
nostic ASCO/CAP guidelines require different signal
values for the evaluation of the HER2 gene status [30].
When using FISH with the CEP17 control, a HER2/CEP17
ratio [2.2 is necessary. If FISH, SISH or CISH (chromo-
genic ISH) is used without a CEP17 control, more than 6
gene copies or clusters of the HER2 gene are sufficient to
determine the HER2 status as positive [6, 7, 30]. If we deal
with aberrant patterns, such as clustering of CEP17 and/or
HER2, standard ASCO/CAP criteria for FISH testing can
be quite difficult to apply, as exact numeration of CEP17
and HER2 copy signals becomes difficult. Precise algo-
rithm for the interpretation of double clustering is not
defined in the ASCO/CAP guidelines. As in co-amplified
cases, the HER2/CEP17 ratio per se will be both mathe-
matically and biologically useless if the HER2 signal count
becomes nearly the same as the CEP17 signal count.
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Co-amplification of both the HER2 and CEP17 region is a
rare event, occurring in less than 1% of the breast cancer
cases tested routinely [17, 23].
In this retrospective study, we present a comprehensive
analysis of 14 breast cancer cases with cluster forming
chromosomal gains on both CEP17 and the HER2 gene by
FISH testing. We compared the evaluation of these cases
and the standard calculation of the HER2/CEP17 ratio
among the three participating institutes. Large HER2
amplicons can overlap numerous genes on 17q and 17p.
Additionally, we tested the potential amplification status of
adjacent genes on 17q and 17p, including TOP2 (Topoi-
somerase 2A), RARA (Retinoic Acid Receptor Alpha) and
TP53. CEP17 was examined using two different probes
covering centromeric and pericentromeric gene sequences
of different lengths. Finally, we correlated the amplifica-
tion status and ratios in all cases to the IHC results of
HER2.
Materials and methods
Study cohort
Fourteen breast cancer cases with an amplified centromeric
region of the chromosome 17 from routine HER2-FISH
testing were retrieved from the diagnostic archives at the
Institute of Surgical Pathology, University Hospital Zurich,
Switzerland and from the Institute of Pathology, Cantonal
Hospital St. Gallen, Switzerland. The age of the patients
ranged between 39 and 76 years (mean age 61.1 years). All
but one tumor corresponded histologically to invasive
ductal carcinoma and one case was an intracystic papillary
carcinoma with invasive components (Table 1). Seven
cases were pT1c, four cases pT2, one case pT3, and two
cases pT4. Axillary lymph node metastases were present in
11 patients and the lymph node status was not known for
one patient (Nr. 14). Eleven carcinomas were hormone
receptor positive. The study was approved by the project
review board at the Institute of Surgical Pathology, Uni-
versity Hospital Zurich, Switzerland.
For the study, paraffin blocks of surgical specimens
were used in 12 cases and core biopsies in 2 cases.
Methods
Fluorescence in situ hybridization (FISH)
Paraffin embedded sections with a thickness of two
micrometers were used for all fluorescence in situ hybrid-
ization analyses. All procedures for the FISH analyses were
carried out by following the recommended protocol of the
manufacturers. Probe mixes were hybridized at 37C
between 14 and 20 h, washed in Rapid-Wash-Solution I at
73C for 5 min, Rapid-Wash-Solution II and H2O for
7 min, air dried and counterstained with DAPI. The reac-
tions were evaluated using an Olympus computer guided
fluorescence microscope (BX61, Olympus Schweiz AG,
Volketswil, Switzerland). Each case was accompanied by a
corresponding hematoxylin and eosin (H&E) stain in order
to identify the invasive tumor component. The HER2 status
was analyzed in all 14 cases by the participating institutes
(Zurich and Cleveland). Seven of the 14 cases from
St.Gallen were tested during the weekly routine FISH
Table 1 Clinico-pathological parameters of the patients
Case Nr. Age (years) Histology TNM stage ER PR
1 63 Invasive ductal carcinoma pT2, pN1 neg neg
2 71 Invasive ductal carcinoma pT3, pN1 5% 5%
3 73 Invasive ductal carcinoma pT4b, pN1 60% neg
4 76 Invasive ductal carcinoma pT2, pN1 1% 1%
5 61 Invasive ductal carcinoma pT1c (m), pN1 90% 80%
6 59 Invasive ductal carcinoma pT1c (m), pN1 neg 100%
7 53 Invasive ductal carcinoma pT4b, pN2 30% 20%
8 64 Invasive ductal carcinoma pT2, pN1 40% neg
9 39 Invasive ductal carcinoma pT1c, pN1 100% 90%
10 60 Invasive papillary carcinoma pT1c, pN0 4% neg
11 49 Invasive ductal carcinoma pT1c, pN2 14% 3%
12 60 Invasive ductal carcinoma pT1c, pN0 80% neg
13 74 Invasive ductal carcinoma pT2, pN1 75% neg
14 54 Invasive ductal carcinoma pT1c, pNx 85% 95%
ER estrogen receptors, PR progesterone receptors. Positivity for hormone receptors is indicated as percentage of positively stained invasive
tumor cells
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diagnostics. All other tests were carried out at the Institute
of Surgical Pathology, University Hospital Zurich,
Switzerland.
HER2 gene
The HER2 gene was tested by using a dual fluorescence kit
(PathVysion
TM
, Vysis, Abbott AG, Diagnostic Division
Baar, Switzerland) containing the HER2 gene (17q11.2–
q12, directly labeled with fluorescent spectrum orange) and
CEP17 (17p11.1–q11.1, directly labeled with fluorescent
spectrum green) (Fig. 2).
CEP17–D17Z1 (centromeric region of chromosome 17)
locus 1
For this locus, a kit labeling the region 17p11.1–q11.1
(D17Z1) of CEP17 (Vysis, Abbott AG, Diagnostic Divi-
sion Baar, Switzerland) was used (Fig. 2). The probe
contained a direct fluorescent labeled area with spectrum
aqua.
CEP17–D17S122/HER2 (centromeric region/HER2
gene on chromosome 17) locus 2
For this locus, the probe D17S122, covering the region
17p11.2–p12, was used (Fig 2). The area was visualized by
direct fluorescent labeling containing spectrum green. The
reactions were carried out on all 14 cases at the Section of
Molecular Pathology, Cleveland Clinic. All probes for this
locus (along with HER2) were graciously provided by Dr.
Robert Jenkins of the Mayo Clinic (Rochester, Minnesota,
USA). Spectrum green labeled D17S122-1 (RP11-465O5),
D17S122-2 (RP11-726O12), D17S122-3 (RP11-924A14)
and D17S122-4 (RP11-136M15). Spectrum orange labeled
HER2 BAC1 (RP11-94L15), and HER2 BAC2 (CTD-
2019C10). All these probes were used to generate the
HER2/D17S122 probe cocktail. HER2 was labeled with
spectrum orange and D17S122 was labeled with spectrum
green. The slides were probed with 1 ll HER2 probe, 2 ll
D17S122 probe, 2 ll human placenta DNA and 5 ll
hybrisol and incubated overnight at 37C.
RARA gene
For the RARA locus, a combined probe of LSIPML/RARA
(Vysis, Abbott AG, Diagnostic Division Baar, Switzerland)
was applied. The RARA gene (17q21.1–q21.3) was directly
labeled with the fluorescent spectrum green probe, the
LSIPML (15q22, not assessed in the study) was directly
labeled with fluorescent spectrum orange (Fig. 2).
TOP2 gene
For the TOP2 gene, a triple probe (Vysis, Abbott AG,
Diagnostic Division Baar, Switzerland) was applied con-
taining the HER2 gene (17q11.2–q12, labeled with spec-
trum green), the centromere CEP17 (17p11.1–q11.1,
labeled with spectrum aqua) and the TOP2 gene (17q21.3–
q22, labeled with spectrum orange) (Fig. 2).
TP53 gene
A dual probe (Vysis, Abbott AG, Diagnostic Division Baar,
Switzerland) was used for the TP53 gene, containing the
TP53 gene (17p13.1, labeled with fluorescent spectrum
orange) and CEP17 (17p11.1–q11.1, labeled with fluores-
cent spectrum green) (Fig. 2).
Silver-enhanced in situ hybridization (SISH) for HER2
and CEP17
In seven cases (Nr. 1–7) from the Zurich cohort, the HER2
status was also investigated with a silver enhanced in situ
hybridization dual probe (Inform, Ventana Medical Sys-
tems, Tucson, AZ, USA).
The HER2 DNA probe (catalog Nr.: 780-4332) was
directly labeled with silver and the chromosome 17 probe
(catalog Nr.: 780-4331) was labeled with red. The signals
were detected with the ultraView SISH detection kit and
the ultraView red ISH detection kit. The whole process was
completely automated using Ventana’s Benchmark auto-
stainers according to the manufacturer’s protocol. A cor-
responding H&E control slide was available in each case
for the SISH analysis.
Immunohistochemistry for HER2
Paraffin-embedded sections with a thickness of 2 lm were
used for the immunohistochemistry. Detection of the HER2
protein was performed with the Ventana Benchmark
automated staining system using Ventana reagents (Ven-
tana Medical Systems, Basel, Switzerland) for the entire
procedure. Primary antibodies were detected using the
iVIEW DAB detection kit and the signal was enhanced
using the amplification kit. The following marker was used:
Pathway anti-HER2, 4B5 (Ventana, Basel, Switzerland;
ready to use without further dilution; concentration,
6 lg/ml).
Guidelines used to interpret the in situ hybridization
(FISH and SISH) in CEP17 and HER2
The ASCO/CAP guidelines were used to interpret the
signals in the FISH and SISH analyses [12, 30]. The
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number of signal copies for CEP17 and HER2 was calcu-
lated for each probe. Optical not separable clusters were set
to 16 copies in the FISH analyses. Furthermore, the ratios
of the dual probes were evaluated. SISH small clusters
were set to 6 copies and larger clusters to 12 copies.
Similarly, a ratio [2.2 was set as an amplified status and
ratios \1.8 were negative. We used definitions from
recently published recommendations by Vance et al. when
we were dealing with intratumoral heterogeneity: at least 2
(and up to 4) representative fields from the invasive areas
were evaluated. If more than 50% of the invasive tumor
cells in these areas had a HER2/CEP17 ratio higher than
2.2, we considered the tumor as amplified. We used these
criteria to examine all the gene regions named above:
HER2, CEP17, RARA, TOP2, and TP53 [16, 25, 27].
The counting and interpretation of the FISH-HER2
signals were performed individually at each institute (ZV,
GB, RT, ZW, YS, DK, CO). Signals for SISH-HER2 and
FISH-TOP2 were analyzed and counted in Zurich (ZV).
The reading and counting of FISH-CEP17 (1), FISH-TP53
and FISH-RARA signals were carried out both in Zurich
(ZV) and in St.Gallen (DK, CO). Finally, the evaluation of
the FISH-D17S122/HER2 signals was performed in
Cleveland (RT, ZW, YS).
Guidelines for the interpretation of the HER2
immunohistochemistry
The ASCO/CAP guidelines were used to interpret the
staining of the HER2 protein expression and scored as
follows: 0 (no staining), 1? (weak and incomplete mem-
brane staining), 2? (strong, complete membrane staining
in less than 30% of the invasive tumor cells or weak/
moderate heterogeneous complete staining in more than
10% of the invasive tumor cells), and 3? (strong complete
homogenous membrane staining in more than 30% of the
invasive tumor cells) [12, 30].
Interpretation of HER2 Status by HER2/CEP17 ratios
Although both the HER2 gene and the CEP17 region
exhibited ‘amplification’ separately in each case, there was
a huge discrepancy regarding the exact HER2 status of
these tumors (Table 3). In 5 of 14 cases (35%) the ratios
ranged from 1.1 to 14.3 between the three institutions.
These problematic cases included 2 tumors with an
immunoreactivity of 3? and 3 tumors with an immunore-
activity of 2?. In 9 of 14 cases (64%) the institutions
reached an agreement on the HER2 status as amplified or
non-amplified, even though the individual ratios varied.
We used the criteria mentioned above in the guide-
lines for the in situ hybridization for all the gene regions
[16, 25, 27]. In one institute, the exact method of counting
required an electronic excel data sheet as described in
previous publications [16, 25, 27]. The other two institu-
tions used direct counting on the computer screen and/or on
the fluorescence microscope. Discrepant signal interpreta-
tion was principally due to the choice of either reporting
the HER2/CEP17 ratio or to reporting the raw signal data.
For example, counting 60 cells (as happened in case Nr. 8)
showed 1037 HER2 and 1007 CEP17 signals. The HER2
gene count of 17.28 would imply amplification, whereas
the CEP17 gene count of 16.78 would mean high chro-
mosomal gain using the recommendations suggested by
Viale et al. in his discussion for real polysomic cases
[16, 25, 27]. According to the ASCO/CAP guidelines on
the other hand, this case is classified as non-amplified as
the HER2/CEP17 ratio is ‘only’ 1.03 [12, 30].
Results
In situ hybridization
HER2-FISH
In six cases (Nrs. 4,8,10,11,12,14) we found multiple large
clusters, in four cases (Nrs. 1, 2, 5, 7) clusters and gene
copies ([5), in four cases (Nrs. 3, 6, 9, 13) multiple copies
of the HER2 gene were present ([5, up to 20–25 gene
copies) (Figs. 1, 3a, 4a, b; Tables 2, 3).
HER2-CEP17 SISH
Seven cases (case Nrs. 1–7) were tested with SISH. In all 7
cases, the HER2 gene was present either in[5 copies and/
or in large clusters (100%) (Fig. 3c). In 3 of 7 cases, both
HER2 and CEP17 were present in clusters (Nrs. 1, 2, 4). In
cases Nr. 5 and Nr. 7, CEP17 and the HER2 gene showed
large cluster formations as well as multiple gene copies (up
to 8 gene copies). In case Nr. 6 both CEP17 and HER2
displayed multiple gene copies (CEP17 up to 8 copies and
the HER2 gene up to 25 copies). Case Nr. 3 showed [5
HER2 gene copies (5–8) and up to 8 CEP17 copies.
CEP17 (locus 1)
CEP17 (locus 1) was analyzed both with a dual HER2
probe as well as with a single probe.
CEP17 (locus 1) dual probe:
All 14 cases (100%) revealed cluster formation and/or mul-
tiple copies of CEP17 (locus 1) (Fig. 1, Table 2). In 6 cases
(Nrs. 4, 5, 9, 10, 12, 13) CEP17 was visualized as solitary
large clusters (Fig. 3d, 4c). In another 6 cases (Nrs. 1, 2, 7, 8,
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11, 14), we found both clusters and up to 8 gene copies. Two
cases (Nrs. 3, 6) revealed up to 8–12 gene copies.
CEP17 (locus 1) single probe
Case Nr. 12 could not be evaluated for this region with the
single probe, as no clear signals could be achieved after
repeated testing. Large clusters were seen in 3 cases (Nrs.
1, 2, 4). In 4 cases (Nrs. 5, 7, 8, 14), CEP17 was found in
clusters and up to 8 gene copies. Two cases (Nrs. 3, 6)
revealed up to 8 gene copies and in case Nrs. 9, 10, 11, 13
there were small clusters.
D17S122/HER2 (locus 2)
Three of 14 cases (21%) showed multiple copies of
D17S122 (locus 2) (Table 2). The average number of
copies was 5.5 (Nr. 3), 3.1 (Nr. 6) and 7.1 (Nr. 7). HER2
was present with [5 copies in 9 of 14 cases and with \5
copies in 5 of 14 cases (Fig. 1).
RARA gene
Ten of 14 cases (71%) revealed amplification of the RARA
gene (Table 2; Figs. 1, 3b). In 2 cases (Nrs. 9 and 10),
amplification was a focal finding (at least in 60 cells) and in
all the other cases, tumor cells were diffusely amplified. In
2 cases (Nrs. 1, 4), large clusters and up to 8 gene copies
were detected. In 5 cases (Nrs. 7, 8, 9, 10, 14), RARA was
present in large clusters, and in 3 cases (Nrs. 5, 6, 11) in
multiple copies (up to 8). Case Nr. 12 could not be ana-
lyzed with this probe as no clear signals were visible.
TOP2 gene
Three of 14 cases (21%) showed an amplified TOP2 region
with up to 8 separate gene copies visible in two cases
Fig. 1 Graphical representation
of amplified gene regions on
chromosome 17. Amplification
is meant as absolute gene copy
number of at least 6 or the
presence of clusters in more
than 50% of the tested invasive
tumor cells
Fig. 2 Anatomical portrayal of the investigated gene loci on
chromosome 17
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Fig. 3 Different amplification patterns in cluster forming chromo-
somal gain on 17q. a FISH HER2/CEP17 dual probe (Vysis): HER2:
orange, CEP17: green, both are in partially overlapping clusters.
b FISH RARA/LSIPML dual probe (Vysis): RARA clusters in green
coloration, LSIPML not photographed. c SISH HER2/CEP17 dual
probe (Ventana), HER2: black, CEP17: red, both genes display large
overlapping clusters. d FISH CEP17 single probe (Vysis): CEP17: in
spectrum aqua, in large clusters
Fig. 4 High magnification of HER2/CEP17 amplicons in the same
two carcinoma cells: a FISH HER2/CEP17 dual probe (Vysis):
HER2: orange, CEP17: green, both signals in partially overlapping
clusters. b FISH HER2 (dual probe with CEP17) (Vysis): HER2:
orange in large clusters, CEP17 is switched out. c FISH CEP17 (dual
probe with HER2) (Vysis): CEP17: green in large clusters, HER2 is
not photographed
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(Nrs. 1, 14), and in case Nr. 8 large clusters were visible
(Fig. 1; Table 2). The CEP17 (locus 1) gene status, ana-
lyzed along with TOP2, was found to be identical to the
CEP17 gene status analyzed with the HER2/CEP17 dual
probe.
TP53 gene
We could not identify any cases with TP53 amplification or
chromosomal gain (Fig. 1; Table 2). All 14 cases revealed
2–3 gene copies of this gene (0/14), indicating that there
are no cases with a high chromosomal gain in our cohort.
As the dual probe also contained the CEP17 region, this
was also assessed. We found a 100% concordance when
compared to the dual HER2/CEP17 (locus 1) probe,
pointing to an amplified CEP17 (locus 1) in all cases.
HER2 immunohistochemistry
Nine of 14 cases (64%) displayed score 3 membranous
stains (Table 3). Eight of these were also FISH positive
(89%). One 3? tumor (Nr. 10) displayed scattered areas
(hotspots with at least 60 cells) containing amplified cells
with FISH. Three of 14 cases were scored as 2? (21.5%)
and all these 2? cases were problematic in the FISH
analysis, as the ratio calculation (HER2/CEP17) resulted in
diverging values. One case (Nr. 13) was scored as 1?
(7%). This case had a heterogenous pattern between the
HER2-IHC and the HER2-FISH as only scattered areas
(hotspots of at least 60 cells) were amplified with FISH.
This case (Nr. 13) had up to 6 HER2 gene copies and small
CEP17 clusters. If counting the absolute HER2 gene copy
number, 6 gene copies would qualify this case as amplified.
Table 2 Summary of the fluorescence in situ hybridization (FISH) on the tested loci on chromosome 17. Numbers indicate number of cases
(total n = 14)
Probe (locus) Eusomic gene Clusters and/
or gene copies [5
Intratumoral
heterogeneity
No signals
TP53 17p13.1 14 0 0 0
D17S122 (locus 2) 17p11.2–p12 11 3 0 0
CEP17 (locus 1) 17p11.1–q11.1 0 14 3 0
HER2 17q11.2–q12 0 14 3 0
RARA 17q21.1–q21.3 3 10 2 1
TOP2 17q21.3–q22 11 3 3 0
CEP17 gene status refers to the whole cohort (including summarized results both with a dual as well as with the single probe)
Table 3 Differential calculation of HER2/CEP17 ratios in the participating institutions. IHC: Immunohistochemistry. FISH: fluorescence in situ
hybridization
Case Nr. HER2 IHC Ratio: HER2/CEP17 Ratio: HER2/CEP17 Ratio: HER2/CEP17 Diagnostic
concordanceFISH FISH FISH
Institution I Institution II Institution III
1 3? [2.2 7.6 Not done Yes
2 3? [2.2 10.7 Not done Yes
3 0 1.0 0.4 Not done Yes
4 3? [2.2 17.3 Not done Yes
5 3? [2.2 5.4 Not done Yes
6 3? [2.2 6.3 Not done Yes
7 3? [2.2 2.8 Not done Yes
8 3? [2.2 14.3 1.1 No
9 2? \1.8 2.5 0.55 No
10 3? [2.2 1.0 1.28 No
11 3? [2.2 13.4 2.89 Yes
12 2? [2.2 1.3 1.16 No
13 1? \1.8 1.2 0.96 Yes
14 2? [2.2 8.4 1.9 No
Positive HER2 status 9/14 (64%) 11/14 (78%) 10/14 (71%) 1/7 (14%)
Disconcordant cases 5/14 (35%)
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Calculating the HER2/CEP17 ratio (ratios: 1.2, 1.8 and
0.96, respectively) (Table 3), this resulted in a non-
amplified status. One case (Nr. 3) showed a negative
immunostaining (7%). This case had a minimum of 8
HER2 and 8 CEP17 gene copies. The absolute HER2 gene
copy number would be sufficient for a positive HER2
status. On the other hand, calculating the HER2/CEP17
ratio (0.4 and 1.0, respectively) results in a negative status.
Discussion
We identified CEP17/HER2 co-amplification in a series of
HER2-FISH assays, and as a result we investigated the
nature of the chromosomal region spanning HER2 and
CEP17 with different FISH probes to additional loci
(TP53, 17p11.1–q11.1, 17p11.2–p12, RARA, and TOP2).
We also examined the HER2 gene with SISH and the
HER2 protein expression with IHC. The assessment of the
co-amplification by FISH was highly diverse in the dif-
ferent laboratories due to missing ASCO/CAP HER2 assay
guidelines for this situation. Twelve of 14 cases showing a
CEP17/HER2 co-amplification had a HER2 score of either
3? or 2?.
During the last decade the diagnosis of breast cancer has
become standardized worldwide by identifying a positive
HER2 status by means of immunohistochemistry and FISH
[12, 20, 30]. HER2-FISH and HER2 immunohistochemistry
assays represent predictive oncologic assays, whereby the
staining intensity and gene alterations are characterized by
distinct cut-off values of positive signals, and a clear algo-
rithm for the interpretation of the signals exists [12, 20, 30].
Using HER2 test kits approved by the US Food and Drug
Administration (FDA), a strong circular membranous stain
in more than 30% of the tested tumor area is defined as a
positive HER2 status via immunohistochemistry [12, 30].
Although a positive HER2 status by means of in situ
hybridization has been distinctly defined according to the
ASCO-CAP guidelines, there are subtle differences in clas-
sifying an amplified status when using different labeling
technologies [20, 30].
The most widely used assay, the HER2-FISH analysis,
requires a ratio [2.2 for the copy numbers of HER2 to
CEP17 for an amplified status [20, 30]. The ASCO/CAP
guidelines, however, do not define the role of a chromo-
somal gain [20, 30]. A HER2/CEP17 ratio can be mis-
leading in cases showing an extremely high chromosomal
gain, as seen in many of our discrepant cases (Figs. 3, 4).
On the other hand, the presence of large clusters of the
HER2 gene or more than six, respectively, 10 dots of the
HER2 gene are sufficient to deal with a positive HER2
status when using silver or chromogenic enhanced in situ
hybridization technology (CISH, SISH) [30].
An accurate count of the copy number of the CEP17
region turned out to be quite problematic in our 14 diag-
nostic HER2-FISH cases, as both the CEP17 region and the
HER2 gene occurred as clusters, to a greater extent as large
and to a lesser extent as small clusters. As the exact copy
number of both CEP17 and the HER2 gene are required for
the assessment of the HER2/CEP17 ratio using ASCO/
CAP criteria, we were confronted by a scenario for which
there is no recommendation in the current guidelines [30].
By using SISH technology, however, 5 of the 7 tested
cases would easily have qualified as amplified for HER2, as
the presence of HER2 clusters alone adequately fulfill these
criteria [30]. Similarly, in a recent paper Marcio` et al. [14]
showed that [6 HER2 gene copies is considered as a
therapeutically important amplification, as true CEP17
polysomy very rarely occurs. In this microarray-based
comparative genomic hybridization (aCGH) study, Marcio`
et al. [14] demonstrated that an abnormal CEP17 copy
number is most likely due to the amplification of the
CEP17 region regardless of the copy number gains of the
short and long arms.
As none of our cases showed an amplification of the
TP53 gene, but instead a chromosomal gain with 2–3 sig-
nals, this indicates that we do not have true polysomic
cases in this series. All our cases appear to show large
amplicons of the HER2 gene spanning at variable lengths
to the centromeric region. Theoretically, it is possible that
large HER2 and CEP17 signals are optically inseparable by
using one single bandpass filter.
We compared the interpretation of the cluster formation
on CEP17 and the HER2 gene by using the ASCO/CAP
guidelines between the three participating institutions and
found an enormous discrepancy in the final results. An
agreement on the FISH-HER2 status using the HER2/
CEP17 ratio as negative or positive could only be reached
in 9 of 14 cases (64%) even though cluster formation of the
HER2 gene was present in most cases. The ratios varied
between 1.1 and 14.3 in the discrepant cases. This was due
to the simple mathematical fact that the CEP17 and HER2
copy numbers were equal or very similar resulting in a
practically unusable ratio.
In such situations, following other recommendations, an
absolute HER2 gene copy count of [6 will fulfill the
criteria for a HER2 positive status in all cases (100%)
[16, 25, 27]. Although not included in the ASCO/CAP
guidelines, there are papers that propagate their ‘own
made’ criteria, at least for the numeration of the HER2
gene in the case of cluster formation. Tight clustering of
the HER2 gene was defined by Simon et al. [21] as being
equivalent to 5 gene copies by FISH testing. The classifi-
cation of small HER2 clusters as being equal to 6 to 10
copies or of large clusters being equal to [10 copies in
CISH HER2 testing by Tanner et al. [22] seem somewhat
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arbitrary but quite practical if it is about ratio calculation.
Then again, several authors avoid defining a random copy
number for the HER2 clusters and instead call them
‘classical clustering’ or admit an ‘imprecise signal
numeration’ as proposed by Lebeau and Sauter [11, 20]. In
co-amplified cases with optically unseparable clusters we
set the definition as 16 copies for FISH and as 12 copies
(large clusters), respectively, 6 copies (small clusters) for
SISH. With this definition, we provided real gene counts,
which reflect the amplification status of the cells more
realistically than the ratios alone. Luckily enough, most
cases showing HER2 gene clustering lack a simultaneous
cluster formation of CEP17 enabling an easy diagnostic
decision on the HER2 status [11, 20].
According to our knowledge, there is only one study
available from 2006 by Troxell et al. on 7 cases with a
corresponding editorial from M. Press, addressing the co-
amplification of CEP17 and the HER2 gene and the
question of how to deal with HER2 testing in such settings
[17, 23]. Troxell et al. [23] proposed an extended FISH
analysis on the neighboring RARA gene adjacent to the
HER2 gene and also adding a HER2 immunohistochemis-
try to the test. Five of their 7 cases were 3? positive on a
protein level and also exhibited an amplification on the
neighboring RARA gene [23].
We took a different approach to characterize the adja-
cent gene regions in the 14 amplified CEP17 regions. On
the one hand, we used a second probe (D17S122) for the
CEP17 region, labeling a much shorter DNA sequence
(17p11.2–p12) than the one in the Vysis kit (17p11.1–
q11.1). Cluster formation of CEP17 was detected in 3 of 14
cases with this shorter probe. In one case (Nr. 3) multiple
separate signals of CEP17 were seen as well. We extended
the adjacent gene regions and additionally tested for the
RARA gene, the distally located TOP2 gene on the long
arm, and the TP53 gene on the short arm of chromosome
17. No amplification was detected for the TP53 gene in any
of the 14 cases, which corroborates with literature data.
TP53 mutations but no amplifications have been found in
sporadic HER2 positive breast cancer [29]. In a recent
study, TP53 protein overexpression was only detected in
unamplified CEP17 polysomic breast cancer cases [10].
The high frequency of RARA co-amplification in our study
(10 of 14 cases, 71%) is very similar to what has already
been reported [14, 23]. Co-amplification of the RARA/
TOP2/HER2 chromosomal regions can occur in other
malignancies as well, as was recently reported in a case of
acute myeloid leukemia [2]. It may be true that the TOP2
gene is virtually always co-amplified with the HER2 gene in
breast cancer, nevertheless, co-amplification frequencies
varying between 30 and 100% has been published [9, 15, 18].
Therefore, the low TOP2/HER2 co-amplification ratio
(21%) in our study probably represents a case selection bias.
In our study, all cases showed a HER2/CEP17
co-amplification. Amplification of CEP17 without involve-
ment of the HER2 gene has been reported in the literature.
Marchio et al. [14] analyzed 5 cases with an amplified
CEP17 region, however, only one of these cases exhibited
[8 HER2 copies, classifying this case as non-amplified by
the HER2/CEP17 ratio.
The presence of multiple gene amplifications on chro-
mosome 17 is a complex process potentially involving a
large HER2 amplicon with further altered telomeric genes
such as TOP2, RARA, GRB7, STARD3 [8, 26]. It is very
likely that the HER2 gene amplification is the first event in
the amplicon formation followed by additional chromo-
somal changes in the telomeric regions [8, 26]. Deletions
and amplifications of other genes have been shown to bear
a predictive value in the response to targeted therapy such
as anthracycline in HER2 positive breast cancer [1, 8, 9, 18,
26].
Comparative genomic hybridization studies have shown
that the long arm of chromosome 17 is particularly prone to
genomic changes. Copy number gains have been identified
most frequently on 17q (57% prevalence) [5]. The forma-
tion of large amplicons and the activation of proto-onco-
genes probably occur through classical amplification
mechanisms such as double minute formations (extra-
chromosomal units) and homogenously stained regions (as
a component of a chromosome) [4, 19].
Between 1999 and 2009, *5,000 FISH-HER2 analyses
were performed in Zurich and St.Gallen. HER2/CEP17
co-amplification was diagnosed in 14 of these cases.
Therefore, co-amplification of CEP17 and the HER2 gene
is a rare event in breast cancer, occurring in less than 1% of
the tested cases.
Accurate interpretation of increased CEP17 and HER2
copy numbers (6 to 10 copies or clusters) is of enormous
importance, as false positive or a negative HER2 status can
occur if testing is not done with consequence as well as
with the correct calculation of the HER2/CEP17 ratio
[3, 13, 17, 23, 24, 28]. If multiple complex genetic alter-
ations are detected on chromosome 17 at routine HER2
testing, then careful evaluation of the HER2 amplicon
along with the potentially co-amplified neighboring genes,
and additional immunohistochemistry for HER2 is neces-
sary [17, 23].
In summary, our data indicate that a complex FISH
pattern with HER2/CEP17 co-amplification requires con-
firmatory HER2 analysis by immunohistochemistry. It is
recommended to report raw FISH data, including CEP17
signals and HER2 signals as well as the HER2 gene count
as the clinically most relevant FISH parameters. Calcula-
tion of the HER2/CEP17 ratio can be misleading as such
patterns can easily be categorized as ‘chromosomal gain’
which can result in a ‘false negative’ HER2 status.
Breast Cancer Res Treat (2012) 132:925–935 933
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Moreover, the testing of chromosomal loci lying far away
from the HER2 region, such as TP53, is very helpful in
defining or ruling out true polysomy.
Acknowledgments The authors wish to thank Dr. Gu¨nter Seile for
providing case Nr. 14 to the study and Dr. Adriana von Teichman for
critical proof-reading and thorough rewriting of the manuscript. There
is no conflict of interest for any of the authors.
References
1. Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan
R, Rodriguez-Pinilla SM, Mackay A, Tamber N, Fenwick K,
Jones C, Dowsett M, Ashworth A, Reis-Filho JS (2008) Genomic
analysis of the HER2/TOP2A amplicon in breast cancer and
breast cancer cell lines. Lab Investig 88:491–503. doi:10.1038/
labinvest.2008.19
2. Asleson AD, Morgan V, Smith S, Velagaleti GV (2010) Ampli-
fication of the RARA gene in acute myeloid leukemia: significant
finding or coincidental observation? Cancer Genet Cytogenet
202:33–37. doi:10.1016/j.cancergencyto.2010.06.003
3. Bartlett JM, Campbell FM, Mallon EA (2008) Determination of
HER2 amplification by in situ hybridization: when should chro-
mosome 17 also be determined? Am J Clin Pathol 130:920–926.
doi:10.1309/AJCPSDG53BEANCYE
4. KV Cotran RS, Robbins SL (1994) Robbins pathologic basis of
disease. W.B. Saunders Company, Philadelphia
5. Dellas A, Torhorst J, Schultheiss E, Mihatsch MJ, Moch H (2002)
DNA sequence losses on chromosomes 11p and 18q are associ-
ated with clinical outcome in lymph node-negative ductal breast
cancer. Clin Cancer Res 8:1210–1216
6. Dietel M, Ellis IO, Hofler H, Kreipe H, Moch H, Dankof A,
Kolble K, Kristiansen G (2007) Comparison of automated silver
enhanced in situ hybridisation (SISH) and fluorescence ISH
(FISH) for the validation of HER2 gene status in breast carci-
noma according to the guidelines of the American Society of
Clinical Oncology and the College of American Pathologists.
Virchows Arch 451:19–25. doi:10.1007/s00428-007-0424-5
7. Fritzsche FR, Bode PK, Moch H, Kristiansen G, Varga Z, Bode B
(2010) Determination of the Her-2/neu gene amplification status
in cytologic breast cancer specimens using automated silver-
enhanced in situ hybridization (SISH). Am J Surg Pathol 34:
1180–1185. doi:10.1097/PAS.0b013e3181
8. Glynn RW, Miller N, Kerin MJ (2010) 17q12–21—the pursuit of
targeted therapy in breast cancer. Cancer Treat Rev 36:224–229.
doi:10.1016/j.ctrv.2009.12.007
9. Hicks DG, Yoder BJ, Pettay J, Swain E, Tarr S, Hartke M, Skacel
M, Crowe JP, Budd GT, Tubbs RR (2005) The incidence of
topoisomerase II-alpha genomic alterations in adenocarcinoma of
the breast and their relationship to human epidermal growth
factor receptor-2 gene amplification: a fluorescence in situ
hybridization study. Hum Pathol 36:348–356. doi:10.1016/j.
humpath.2005.01.016
10. Krishnamurti U, Zarineh A, Atem FD, Silverman JF (2011)
Correlation of immunohistochemical expression of p53 with
unamplified chromosome 17 polysomy in invasive breast carci-
noma. Appl Immunohistochem Mol Morphol 19:28–32. doi:
10.1097/PAI.0b013e3181e9bb6f
11. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt
B, Untch M, Lohrs U (2001) Her-2/neu analysis in archival tissue
samples of human breast cancer: comparison of immunohisto-
chemistry and fluorescence in situ hybridization. J Clin Oncol
19:354–363
12. Lebeau A, Turzynski A, Braun S, Behrhof W, Fleige B, Schmitt
WD, Grob TJ, Burkhardt L, Holzel D, Jackisch C, Thomssen C,
Muller V, Untch M (2010) Reliability of human epidermal
growth factor receptor 2 immunohistochemistry in breast core
needle biopsies. J Clin Oncol 28:3264–3270. doi:10.1200/JCO.
2009.25.9366
13. Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Go-
mez-Galdon M, Veys I, Cardoso F, Sotiriou C, Di Leo A, Piccart
MJ, Larsimont D (2005) Polysomy 17 in HER-2/neu status elab-
oration in breast cancer: effect on daily practice. Clin Cancer Res
11:4393–4399. doi:10.1158/1078-0432.CCR-04-2256
14. Marchio C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C,
Pasini B, Tan DS, Mackay A, Fenwick K, Tamber N, Bussolati
G, Ashworth A, Reis-Filho JS, Sapino A (2009) Does chromo-
some 17 centromere copy number predict polysomy in breast
cancer? A fluorescence in situ hybridization and microarray-
based CGH analysis. J Pathol 219:16–24. doi:10.1002/path.2574
15. Nielsen KV, Muller S, Moller S, Schonau A, Balslev E, Knoop
AS, Ejlertsen B (2010) Aberrations of ERBB2 and TOP2A genes
in breast cancer. Mol Oncol 4:161–168. doi:10.1016/j.molonc.
2009.11.001
16. Ohlschlegel C, Zahel K, Kradolfer D, Hell M, Jochum W (2010)
Intratumoral heterogeneity of HER2 status in breast carcinoma.
Pathologe 31(Suppl 2):292–295. doi:10.1007/s00292-010-1316-z
17. Press MF (2006) How is Her-2/neu status established when Her-
2/neu and chromosome 17 centromere are both amplified? Am J
Clin Pathol 126:673–674. doi:10.1309/GM16-C018-06EF-URX7
18. Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago
A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert
N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti
G, Lindsay MA, Riva A, Slamon DJ (2010) Alteration of topoi-
somerase II-alpha gene in human breast cancer: Association with
responsiveness to anthracycline-based chemotherapy. J Clin
Oncol. doi:10.1200/JCO.2009.27.5644
19. Reddy KS (2007) Double minutes (dmin) and homogeneously
staining regions (hsr) in myeloid disorders: a new case suggesting
that dmin form hsr in vivo. Cytogenet Genome Res 119:53–59.
doi:10.1159/000109619
20. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF (2009)
Guidelines for human epidermal growth factor receptor 2 testing:
biologic and methodologic considerations. J Clin Oncol 27:
1323–1333. doi:10.1200/JCO.2007.14.8197
21. Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, Schraml
P, Bubendorf L, Mihatsch MM, Moch H, Wilber K, Schotzau A,
Kononen J, Sauter G (2001) Patterns of her-2/neu amplification
and overexpression in primary and metastatic breast cancer.
J Natl Cancer Inst 93:1141–1146
22. Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart
MJ, Isola J (2000) Chromogenic in situ hybridization: a practical
alternative for fluorescence in situ hybridization to detect HER-2/
neu oncogene amplification in archival breast cancer samples.
Am J Pathol 157:1467–1472
23. Troxell ML, Bangs CD, Lawce HJ, Galperin IB, Baiyee D, West
RB, Olson SB, Cherry AM (2006) Evaluation of Her-2/neu status
in carcinomas with amplified chromosome 17 centromere locus.
Am J Clin Pathol 126:709–716. doi:10.1309/9EYM-6VE5-8F2Y-
CD9F
24. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan
TM (2001) Discrepancies in clinical laboratory testing of eligi-
bility for trastuzumab therapy: apparent immunohistochemical
false-positives do not get the message. J Clin Oncol 19:
2714–2721
25. Vance GH, Barry TS, Bloom KJ, Fitzgibbons PL, Hicks DG,
Jenkins RB, Persons DL, Tubbs RR, Hammond ME (2009)
Genetic heterogeneity in HER2 testing in breast cancer: panel
summary and guidelines. Arch Pathol Lab Med 133:611–612
934 Breast Cancer Res Treat (2012) 132:925–935
123
26. Vanden Bempt I, Drijkoningen M, De Wolf-Peeters C (2007) The
complexity of genotypic alterations underlying HER2-positive
breast cancer: an explanation for its clinical heterogeneity. Curr
Opin Oncol 19:552–557
27. Viale G (2009) Be precise! The need to consider the mechanisms
for CEP17 copy number changes in breast cancer. J Pathol
219:1–2. doi:10.1002/path.2593
28. Vranic S, Teruya B, Repertinger S, Ulmer P, Hagenkord J,
Gatalica Z (2011) Assessment of HER2 gene status in breast
carcinomas with polysomy of chromosome 17. Cancer
117:48–53. doi:10.1002/cncr.25580
29. Wilson JR, Bateman AC, Hanson H, An Q, Evans G, Rahman N,
Jones JL, Eccles DM (2010) A novel HER2-positive breast
cancer phenotype arising from germline TP53 mutations. J Med
Genet 47:771–774. doi:10.1136/jmg.2010.078113
30. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC,
Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A,
McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes
A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M,
Wheeler TM, Hayes DF (2007) American Society of Clinical
Oncology/College of American Pathologists guideline recom-
mendations for human epidermal growth factor receptor 2 testing
in breast cancer. J Clin Oncol 25:118–145. doi:10.1200/JCO.
2006.09.2775
Breast Cancer Res Treat (2012) 132:925–935 935
123
